Recombinant Dna Technique Included In Method Of Making A Protein Or Polypeptide Patents (Class 435/69.1)
  • Patent number: 11324831
    Abstract: Provided is a novel material used to introduce an exogenous substance into cells. Also provided is a method for introducing an exogenous substance into target cells using this material. The present invention provides an exosome that is used to introduce an exogenous substance into target cells, wherein the exosome contains one type or two or more types of an exogenous substance and a substance that induces macropinocytosis in the target cells. The present invention also provides a composition containing the exosome and a method for introducing an exogenous substance into cells using this exosome.
    Type: Grant
    Filed: May 3, 2017
    Date of Patent: May 10, 2022
    Inventors: Ikuhiko Nakase, Tetsuhiko Yoshida, Nahoko Baileykobayashi
  • Patent number: 11325955
    Abstract: Methods of generating and optimizing stabilized (e.g., stapled and/or stitched) anti-microbial peptides (StAMPs) for the prophylaxis and treatment of antibiotic-resistant (e.g., colistin-resistant, methicillin resistant, meropenem-resistant) bacterial infections (e.g., Gram-negative, Gram-positive), and methods for using such peptides for experimental investigation, livestock management, management of crops/trees/plants, and/or therapeutic benefit. Also featured are methods for reducing renal toxicity of a StAMP.
    Type: Grant
    Filed: July 18, 2018
    Date of Patent: May 10, 2022
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Loren D. Walensky, Rida Mourtada
  • Patent number: 11318188
    Abstract: In some aspects, the disclosure relates to GDF/BMP antagonists and methods of using GDF/BMP antagonists to treat, prevent, or reduce the progression rate and/or severity of pulmonary hypertension (PH), particularly treating, preventing or reducing the progression rate and/or severity of one or more PH-associated complications. The disclosure also provides methods of using a GDF/BMP antagonist to treat, prevent, or reduce the progression rate and/or severity of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, and right ventricular hypertrophy. The disclosure further provides methods of using a GDF/BMP antagonist to reduce right ventricular systolic pressure in a subject in need thereof.
    Type: Grant
    Filed: June 4, 2021
    Date of Patent: May 3, 2022
    Assignee: ACCELERON PHARMA INC.
    Inventors: Ravindra Kumar, John Knopf
  • Patent number: 11312745
    Abstract: The present invention relates to methods of purifying proteins containing Fc regions, such as antibodies and Fc fusion proteins. In particular, the present invention relates to a purification method resulting in reduced levels of aggregate protein comprising adsorbing an Fc region-containing protein to a temperature-responsive protein A resin and eluting the protein from the resin at a temperature below 35 C with an elution buffer comprising a chaotropic agent, a sugar alcohol, and at least one amino acid. Methods of separating fully assembled antibodies from half antibody forms thereof using the elution buffer are also described.
    Type: Grant
    Filed: July 21, 2017
    Date of Patent: April 26, 2022
    Assignee: AMGEN INC.
    Inventor: John K. Kawooya
  • Patent number: 11306130
    Abstract: This invention is in the field of medicinal pharmacology. In particular, the invention relates to protease activated receptor type 3 (PAR3) modulating compounds (e.g., mimetic peptides), compositions comprising such modulating compounds, and their use as therapeutics for the treatment of conditions involving PAR3 activity.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: April 19, 2022
    Assignees: ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA, BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Josef Vagner, Scott A. Boitano, Theodore J. Price, Gregory O. Dussor
  • Patent number: 11292838
    Abstract: The invention relates to a method for generating an antibody binding to a cell surface protein of interest, the method comprising the following steps: (a) providing a non-human cell which does not express the endogenous form of the cell surface protein of interest but expresses an exogenous form of the cell surface protein of interest comprising at least one human segment; (b) immunization of a non-human animal with the cell line provided in step (a); (c) generation of hybridomas from the immunized non-human animal of step (b); (d) screening for an antibody that binds to the cell surface protein of interest by contacting the antibodies secreted by the hybridomas of step (c) with human cells which do not express the endogenous form of the cell surface protein of interest but express an exogenous form of the cell surface protein of interest comprising at least one human segment.
    Type: Grant
    Filed: June 1, 2016
    Date of Patent: April 5, 2022
    Assignee: MEDIGENE IMMUNOTHERAPIES GMBH
    Inventors: Dolores Schendel, Slavoljub Milosevic, Tanja Herrmann, Michaela Kügler
  • Patent number: 11285191
    Abstract: Disclosed are compositions and methods for stimulating immune responses. More particularly, these compositions and methods involve the use of an inhibitor of IL-25 function and an immune stimulator that stimulates an immune response to a target antigen for stimulating protective or therapeutic immune responses to a target antigen. The compositions and methods of the present invention are particularly useful in the prevention and treatment of infections and cancers.
    Type: Grant
    Filed: July 26, 2017
    Date of Patent: March 29, 2022
    Assignee: THE BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE
    Inventors: Ronald James Jackson, Charani Ranasinghe
  • Patent number: 11286497
    Abstract: The present inventions relate to compositions and methods for providing stress tolerant transgenic plants comprising a RING domain zinc-finger motif transcription factor protein. More particularly, the invention relates to compositions and methods comprising a RING-H2 domain transcription factor protein for providing drought and salt tolerant plants, in particular comprising a recombinant XERICO gene and protein.
    Type: Grant
    Filed: August 13, 2018
    Date of Patent: March 29, 2022
    Assignee: Board of Trustees of Michigan State University
    Inventors: Kyung-Hwan Han, Jae-Heung Ko
  • Patent number: 11285190
    Abstract: The present disclosure describes the C-type lectin CLEC11a as a bone growth factor. Clec11a-deficient mice showed reduced bone volume and mineralization, while bone resorption remained unchanged. Administration of recombinant Clec11a systemically promoted bone formation in mice at risk for osteoporosis.
    Type: Grant
    Filed: April 18, 2016
    Date of Patent: March 29, 2022
    Assignee: The Board of Regents of The University of Texas System
    Inventors: Sean Morrison, Rui Yue
  • Patent number: 11286459
    Abstract: An object of the present invention is to provide an animal cell culture method which is high in protein productivity. Provided is a method for culturing animal cells in a culture medium, wherein the culture medium comprises a nucleic acid component(s) (deoxyuridine, thymidine, and/or deoxycytidine, or a salt(s) thereof). Also provided is a method for producing a protein, the method comprising the step of culturing animal cells expressing the protein in a culture medium, wherein the culture medium comprises a nucleic acid component(s).
    Type: Grant
    Filed: May 26, 2016
    Date of Patent: March 29, 2022
    Assignee: Astellas Pharma Inc.
    Inventors: Yasuhiro Takagi, Takuya Kikuchi
  • Patent number: 11279955
    Abstract: Described herein is a process of producing an organic compound, the process including: I) cultivating a genetically modified microorganism in a culture medium including sucrose as an assimilable carbon source to allow the genetically modified microorganism to produce the organic compound, and II) recovering the organic compound from the fermentation broth obtained in process step I) The genetically modified microorganism includes A) at least one genetic modification that leads to an increased activity of the enzyme encoded by the rbsK-gene, compared to the original microorganism that has not been genetically modified, and the original microorganism belongs to the family Pasteurellaceae. Also described herein are a genetically modified microorganism and the use thereof for the fermentative production of an organic compound from sucrose as an assimilable carbon source.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: March 22, 2022
    Assignee: BASF SE
    Inventors: Hartwig Schroeder, Stefan Haefner, Oskar Zelder, Christoph Wittmann, Anna Christine Schroer, Birgit Hoff, Nico Boehmer
  • Patent number: 11279943
    Abstract: Provided is a technique for highly expressing a target protein in a plant cell by using a glycosylation domain, a recombinant vector comprising a gene encoding a fusion protein of a glycosylation domain and a target protein, a recombinant cell, a transformed plant, and a method of producing a target protein using these.
    Type: Grant
    Filed: January 17, 2018
    Date of Patent: March 22, 2022
    Assignee: BIOAPPLICATIONS INC.
    Inventors: In Hwan Hwang, Hyang Ju Kang
  • Patent number: 11274286
    Abstract: The present invention provides engineered deoxyribose-phosphate aldolase polypeptides useful under industrial process conditions for the production of pharmaceutical and fine chemical compounds.
    Type: Grant
    Filed: July 2, 2019
    Date of Patent: March 15, 2022
    Assignee: Codexis, Inc.
    Inventors: Da Duan, Oscar Alvizo, Jovana Nazor, Harvinder Chagger Maniar, James Nicholas Riggins, Jonathan Vroom, Santhosh Sivaramakrishnan, Hao Yang, Anna Fryszkowska, Mark A. Huffman, Joshua N. Kolev, Iman Farasat, Agustina Rodriguez-Granillo, Deeptak Verma
  • Patent number: 11274278
    Abstract: The present invention relates to in vitro-methods of expanding a population of cells such as lymphocytes, comprising contacting a sample comprising a population of cells with a multimerization reagent. The multimerization reagent has reversibly immobilized thereon (bound thereto) a first agent that provides a primary activation signal to the cells and optionally, a second agent that provides a co-stimulatory signal. The invention also provides multimerization reagents, kits, arrangements and an apparatus for expanding cells.
    Type: Grant
    Filed: April 16, 2015
    Date of Patent: March 15, 2022
    Assignee: Juno Therapeutics GmbH
    Inventors: Lothar Germeroth, Christian Stemberger
  • Patent number: 11268101
    Abstract: The disclosure relates to recombinant protein expression systems comprising genetically modified cells wherein the cells are transformed or transfected with tRNA genes to reduce base mismatch due to genetic degeneracy in the genetic code.
    Type: Grant
    Filed: January 9, 2017
    Date of Patent: March 8, 2022
    Assignee: The University of York
    Inventor: Robert White
  • Patent number: 11266688
    Abstract: The present invention provides a glycosylated CEA-specific single-chain antibody, and a chimeric antigen receptor (CAR) targeting a glycosylated CEA, which can be used in manufacture of an agent or a medicament for diagnosis or treatment of a tumor overexpressing glycosylated CEA.
    Type: Grant
    Filed: July 27, 2017
    Date of Patent: March 8, 2022
    Assignees: THE FOURTH MILITARY MEDICAL UNIVERSITY XI'AN, SHANGHAI GENBASE BIOTECH CO., LTD.
    Inventors: Daiming Fan, Yongzhan Nie, Kaichun Wu, Yueqiong Cao, Jijun Yuan, Xuejun Yu
  • Patent number: 11268080
    Abstract: Disclosed herein is a botulinum neurotoxin (BoNT) polypeptide with a modified receptor binding domain (HC) having one or more amino acid mutations that modify the binding of the BoNT to the receptor. Specific mutations and combinations of mutations are also disclosed. Isolated modified HC, polypeptides comprising the modified HC, chimeric molecules, pharmaceutical compositions, and methods of making and using the same are also disclosed. Methods of identifying additional such modified receptor binding domains, are further disclosed.
    Type: Grant
    Filed: March 25, 2016
    Date of Patent: March 8, 2022
    Assignee: President and Fellows of Harvard College
    Inventors: Min Dong, Lisheng Peng, Liang Tao
  • Patent number: 11261470
    Abstract: The present disclosure relates to a recombinant gram-negative bacterial cell comprising: a) a mutant spr gene encoding a spr protein having a mutation at one or more amino acids selected from D133, H145, H157, N31, R62, I70, Q73, C94, S95, V98, Q99, R100, L108, Y115, V135, L136, G140, R144 and G147 and b) a gene capable of expressing or overexpressing one or more proteins capable of facilitating protein folding, such as FkpA, Skp, SurA, PPiA and PPiD, wherein the cell has reduced Tsp protein activity compared to a wild-type cell, methods employing the cells, use of the cells in the expression of proteins in particular antibodies, such as anti FcRn antibodies and proteins made by the methods described herein.
    Type: Grant
    Filed: April 23, 2018
    Date of Patent: March 1, 2022
    Assignee: UCB BIOPHARMA SRL
    Inventors: Philip Jonathan Bassett, David Paul Humphreys, Pareshkumar Manjibhai Patel
  • Patent number: 11261435
    Abstract: The present disclosure refers to an endonuclease-based gene editing construct, wherein the construct comprises a CRISPR-associated endonuclease (such as Cas9 or Cpf1) or a derivative thereof and at least one or more hormone binding domains of the estrogen receptor (ERT2) or derivatives thereof. The present disclosure also describes a method of editing a genome of a host cell using the construct as disclosed herein, the method comprising transfecting the host cell with the nucleic acid sequence as defined herein and incubating the cell with an inducing agent.
    Type: Grant
    Filed: November 7, 2016
    Date of Patent: March 1, 2022
    Assignees: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH, NANYANG TECHNOLOGICAL UNIVERSITY
    Inventor: Meng How Tan
  • Patent number: 11254921
    Abstract: The present invention provides culture mediums that are useful for the expression of ADAMTS proteins, such as ADAMTS13. Methods for the expression and purification of ADAMTS proteins are also provided. In some embodiments, the mediums and methods of the invention are useful for the expression of ADAMTS proteins having high specific activities. Also provided are ADAMTS, e.g., ADAMTS13, protein compositions with high specific activities, which are expressed and purified according to the methods provided herein.
    Type: Grant
    Filed: June 16, 2020
    Date of Patent: February 22, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Leopold Grillberger, Alexandra Spenger, Meinhard Hasslacher, Rana Grillberger, Manfred Reiter
  • Patent number: 11236318
    Abstract: A horseshoe crab Factor C protein having activity of Factor C, wherein the horseshoe crab is selected from Tachypleus tridentatus, Limulus polyphemus, and Carcinoscorpius rotundicauda, and wherein the horseshoe crab Factor C protein is produced through being recombinantly expressed from a Chinese Hamster Ovary (CHO) DG44 cell or HEK cell.
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: February 1, 2022
    Assignee: SEIKAGAKU CORPORATION
    Inventors: Hikaru Mizumura, Toshio Oda, Shun-ichiro Kawabata
  • Patent number: 11237165
    Abstract: Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is a common human, human-like, or humanized light chain. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.
    Type: Grant
    Filed: July 18, 2017
    Date of Patent: February 1, 2022
    Assignee: Merus N.V.
    Inventors: Ton Logtenberg, Mark Throsby, Robert A. Kramer, Rui Daniel Pinto, Cornelis A. de Kruif, Erwin Houtzager
  • Patent number: 11237177
    Abstract: The present disclosure provides methods for identifying compounds that modulate the activity and/or expression of GPR92, wherein said compounds can be incorporated into flavor compositions that can be used to modify the taste and/or palatability of pet food products. In certain non-limiting embodiments, the present disclosure provides a method for identifying a composition that modulates the activity of a GPR92 receptor comprising (a) contacting a test agent with a GPR92 receptor, (b) determining the activity of the GPR92 receptor, and (c) selecting as the composition, a test agent that increases the activity of the GPR92 receptor.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: February 1, 2022
    Assignee: MARS, INCORPORATED
    Inventors: Scott Joseph McGrane, Matthew Ronald Gibbs, Richard Masten Fine, Boris Klebansky
  • Patent number: 11230583
    Abstract: The present invention relates to inhibin analogs, their method of production and their use in the treatment and prophylaxis of disease or conditions associated with reduced levels of inhibin and activin-mediated signaling.
    Type: Grant
    Filed: November 25, 2016
    Date of Patent: January 25, 2022
    Assignee: Hudson Institute of Medical Research
    Inventors: Craig Harrison, Kelly Walton
  • Patent number: 11219680
    Abstract: The present invention provides immunogenic compositions having one or more polysaccharide-protein conjugates in which polysaccharides obtained from bacterial capsules are conjugated to diphtheria toxin fragment B (DTFB) or a variant thereof. The immunogenic compositions may be multivalent pneumococcal polysaccharide conjugate compositions in which polysaccharides from one or more Steptococcus pneumoniae serotypes are conjugated to diphtheria toxin fragment B (DTFB) and, optionally, additional polysaccharides from one or more different Steptococcus pneumoniae serotypes are conjugated to one or more other carrier proteins.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: January 11, 2022
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: John E. MacNair, Michael A. Winters, Thomas Svab, Sheng-Ching Wang, William J. Smith, Cecilia Giovarelli
  • Patent number: 11214790
    Abstract: Provided are a method for obtaining an HNL gene and HNL derived from a millipede other than Chamberlinius hualienensis, and preparing a practically useable amount of HNL; and a method for producing optically active cyanohydrin using this HNL. A method for producing a millipede-derived HNL gene. A method that includes the selection of a gene having a base sequence that encodes a conserved amino acid sequence TAX1DIX2G (SEQ ID NO: 15) or VPNGDKIH (SEQ ID NO: 16) of millipede-derived HNL from genes present in an organism belonging to the Diplopoda. A protein having an amino acid sequence of any of (1)-(3) and having HNL activity. (1) An amino acid sequence listed in any of SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 83, 85, 87, or 89; (2) an amino acid sequence having amino acids deleted, substituted, and/or added in an amino acid sequence of (1); or (3) an amino acid sequence having 90% or greater identity to an amino acid sequence of (1).
    Type: Grant
    Filed: February 28, 2017
    Date of Patent: January 4, 2022
    Inventors: Yasuhisa Asano, Takuya Yamaguchi
  • Patent number: 11213592
    Abstract: The present disclosure relates to, among other things, antibody-drug conjugates comprising a STING agonist cyclic di-nucleotide conjugated to an antibody, preparation methods therefor, and uses therefor.
    Type: Grant
    Filed: May 11, 2021
    Date of Patent: January 4, 2022
    Assignees: IMMUNESENSOR THERAPEUTICS, INC., THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Zhijian Chen, Heping Shi, Qi Wei, Chuo Chen, Lijun Sun, Jian Qiu, Youtong Wu
  • Patent number: 11207382
    Abstract: Methods and compositions for treating symptoms of conditions such as but not limited to osteoarthritis and rheumatoid arthritis. The methods may feature direct intraarticular injection of a recombinant self-complementary adeno-associated virus (sc-rAAV) with a vector adapted to express a modified IL-1Ra peptide. The methods of the present invention may express a therapeutically effective amount of the modified IL-1Ra peptide so as to ameliorating symptoms associated with the condition being treated.
    Type: Grant
    Filed: August 18, 2017
    Date of Patent: December 28, 2021
    Assignee: University of Florida Research Foundation, Incorporated
    Inventor: Steven C. Ghivizzani
  • Patent number: 11197910
    Abstract: The present invention relates to the use of phosphotidylserine or pathogenic sugar targeted therapeutics for the management and treatment of microbial infections, including Zika, Dengue, West Nile, Ebola, H1N1, enteroviruses, Leishmaniasis, Malaria and Coronaviruses SARS-COV.
    Type: Grant
    Filed: August 19, 2020
    Date of Patent: December 14, 2021
    Assignee: VITRUVIAE LLC
    Inventors: Mahiuddin Ahmed, Sonia Sequeira
  • Patent number: 11198879
    Abstract: The present invention provides novel reagents and a cloning procedure based on homologous recombination for the site-directed cloning of a DNA fragment to a vector at designed site(s). The cloning reagents are made of mixture of extracts from at least two different cell types, preferably a mixture made of extracts from wild-type E. coli and S. cerevisiae. Due to the activity of the mixture of cell extracts, recombination occurs between the 3? and 5?-ends of the target DNA and at the ends of linearized vector, which facilitates in-frame construction of expression vectors.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: December 14, 2021
    Assignee: VIET NAM NATIONAL UNIVERSITY HO CHI MINH CITY
    Inventors: Phuong Thao Thi Dang, My Trinh Thi Nguyen, Nghia Hieu Nguyen, Thuoc Linh Tran
  • Patent number: 11193154
    Abstract: The present invention is directed to a cell-free system for producing a glycosylated protein. This system comprises an isolated oligosaccharyltransferase capable of transferring a glycan from a lipid carrier molecule to a glycoprotein target, one or more isolated glycans, where each glycan is linked to a lipid carrier molecule, and a glycoprotein target comprising one or more glycan acceptor amino acid residues or a nucleic acid molecule encoding said glycoprotein target. The present invention further relates to kits and methods for producing a glycosylated protein in this cell-free system.
    Type: Grant
    Filed: November 5, 2012
    Date of Patent: December 7, 2021
    Assignee: CORNELL UNIVERSITY
    Inventor: Matthew Delisa
  • Patent number: 11186632
    Abstract: This description provides novel strategies and methods for treatment of hyperproliferation conditions such as keloids, lung fibrosis, and lung cancer with the use of bi-functional molecules that target growth factors. A bifunctional hepatoma-derived growth factor (HDGF)-specific antibody for these methods comprises at least one complementarity determining region (CDR) specific for HDGF, at least one receptor domain that specifically binds to a growth factor selected from vascular endothelial growth factor (VEGF) and transforming growth factor beta (TGF?).
    Type: Grant
    Filed: August 15, 2017
    Date of Patent: November 30, 2021
    Assignee: UNIVERSITY OF MARYLAND, BALTIMORE
    Inventors: Li Mao, Hening Ren
  • Patent number: 11185528
    Abstract: Methods of treating or preventing allergic or pulmonary diseases characterized by endothelial dysfunction with Alda-1 are presented. Treatment of pulmonary endothelial cells subjected to hyperoxia with Alda-1 showed an increase in ALDH2 activity and expression. Treatment with Alda-1 also illustrated a decrease in oxidative stress, a decrease in reactive oxygen species (ROS), a decrease in apoptosis, a decrease in inflammation and an enhancement of mitochondrial membrane potential.
    Type: Grant
    Filed: April 3, 2020
    Date of Patent: November 30, 2021
    Assignee: University of South Florida
    Inventors: Narasaiah Kolliputi, Richard F. Lockey, Lakshmi Galam
  • Patent number: 11179442
    Abstract: The present invention provides new protease-resistant polypeptides, as well as compositions and methods for treating, ameliorating or preventing conditions related to joint damage, including acute joint injury and arthritis.
    Type: Grant
    Filed: May 6, 2019
    Date of Patent: November 23, 2021
    Assignee: NOVARTIS AG
    Inventors: Kristen Johnson, Jian Shi
  • Patent number: 11174494
    Abstract: The invention pertains to an expression vector or a combination of at least two expression vectors comprising at least (a) a polynucleotide encoding a product of interest or an insertion site for incorporating a polynucleotide encoding a product of interest; (b) a polynucleotide encoding a first selectable marker (sm I); (c) a polynucleotide encoding a second selectable marker (sm II), which is different from the first selectable marker (sm I), wherein the activity of the selectable marker (sm I) or (sm II) is at least partially influenced by the activity of the other selectable marker and wherein the selectable markers (sm I) and (sm II) are involved in the folate metabolism. Also provided are suitable host cells, selection methods and methods for producing polypeptides with high yield.
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: November 16, 2021
    Assignee: Novartis AG
    Inventors: Thomas Jostock, Hans-Peter Knopf
  • Patent number: 11168310
    Abstract: Disclosed herein are compositions and methods of treating disclosure provides for compounds for use in treating Mitochondrial Neurogastrointestinal Encephalopathy Syndrome (MNGIE). In some embodiments, the compounds have cell penetrating activity and thymidine phosphorylase activity. In certain embodiments, the compounds disclosed herein comprise: a) at least one cell-penetrating peptide (CPP) moiety; and b) a thymidine phosphorylase, or an active fragment or analog thereof (TP), wherein the CPP is coupled, directly or indirectly, to TP.
    Type: Grant
    Filed: March 17, 2020
    Date of Patent: November 9, 2021
    Assignee: Entrada Therapeutics, Inc.
    Inventors: Natarajan Sethuraman, Jason Ruth, Lou A. Tartaglia, Dehua Pei, Ziqing Qian
  • Patent number: 11155781
    Abstract: The present disclosure describes methods of maintaining the phenotype of differentiated cells. Generally, the natural environment of the body is replicated for the differentiated cell. The differentiated cell is plated on a cell culture substrate comprising a laminin, such as laminin-521 or laminin-511. The substrate may also contain a cadherin. This maintains the phenotype of the differentiated cell.
    Type: Grant
    Filed: November 14, 2016
    Date of Patent: October 26, 2021
    Assignee: BIOLAMINA AB
    Inventors: Karl Tryggvason, Karl Kristian Tryggvason, Anna Domogatskaya
  • Patent number: 11142756
    Abstract: The disclosure relates to acetyl-CoA carboxylase (ACC) variants and host cells expressing them for the production of malonyl-CoA derived compounds including fatty acid derivatives. Further contemplated are methods of producing increased amounts of malonyl-CoA derived compounds and related cell cultures.
    Type: Grant
    Filed: February 26, 2020
    Date of Patent: October 12, 2021
    Assignee: Genomatica, Inc.
    Inventors: Derek L. Greenfield, Donald E. Trimbur, Andreas W. Schirmer, Cindy Chang, Behnaz Behrouzian, Jessica Winger
  • Patent number: 11136586
    Abstract: The invention relates to an in vitro cell-free expression system incorporating a novel inorganic polyphosphate-based energy regeneration system. In certain embodiments, the invention includes a cell-free expression system where the cellular energy source, ATP, is regenerated from inorganic polyphosphate using a dual enzyme system. In this embodiment, this dual enzyme system may include thermostable Adenosyl Kinase, and/or Polyphosphate Kinase enzymes.
    Type: Grant
    Filed: January 2, 2018
    Date of Patent: October 5, 2021
    Assignee: NTxBio, LLC
    Inventors: Alexander Koglin, Michael Humbert
  • Patent number: 11136549
    Abstract: The invention is directed to modified T cells, methods of making and using isolated, modified T cells, and methods of using these isolated, modified T cells to address diseases and disorders. In one embodiment, this invention broadly relates to TCR-deficient T cells, isolated populations thereof, and compositions comprising the same. In another embodiment of the invention, these TCR-deficient T cells are designed to express a functional non-TCR receptor. The invention also pertains to methods of making said TCR-deficient T cells, and methods of reducing or ameliorating, or preventing or treating, diseases and disorders using said TCR-deficient T cells, populations thereof, or compositions comprising the same.
    Type: Grant
    Filed: April 10, 2017
    Date of Patent: October 5, 2021
    Assignee: THE TRUSTEES OF DARTMOUTH COLLEGE
    Inventor: Charles L. Sentman
  • Patent number: 11122817
    Abstract: The present invention provides a protein material and food ingredient from a sustainable and stable source. The sustainable and stable source of the food or food ingredient is cellular biomass, for example an algal or microbial biomass. The invention discloses that the cellular biomass can be subjected to a series of steps to derive the protein material and food or food ingredient, which has high nutritional content and has pleasing organoleptic properties.
    Type: Grant
    Filed: January 25, 2016
    Date of Patent: September 21, 2021
    Assignee: Smallfood Inc.
    Inventors: George C. Rutt, James H. Flatt, Peter Domaille, Gerardo V. Toledo, Daniel G. Dueppen
  • Patent number: 11123579
    Abstract: The detergent product for cosmetic use, comprises: a base compound having a detergent action; spores of probiotic bacteria mixed with the base compound; bacteriophage elements mixed with the base compound and having bactericide activity on predetermined undesired bacterial species present, the bacteriophage elements, in cooperation with the spores of probiotic bacteria, being able to carry out a combined and synergic action against damaging micro-organisms. Use of the detergent product is also described, for cleansing of the skin, skin adnexa (hair, nails, body hair, beard), of the oral cavity, mucosa or the teeth.
    Type: Grant
    Filed: September 21, 2017
    Date of Patent: September 21, 2021
    Assignee: COPMA S. C. A. R. L.
    Inventors: Alberto Rodolfi, Elisabetta Caselli
  • Patent number: 11123369
    Abstract: Disclosed herein are methods of engineering a bi-specific T-cell expressing chimeric antigen receptors for promoting the in vivo expansion and activation of an effector cell and a second chimeric antigen receptor or TcR specific for a ligand on a tumor. Methods of administering to subjects in need, bi-specific chimeric antigen receptor bearing cells are also provided.
    Type: Grant
    Filed: November 3, 2020
    Date of Patent: September 21, 2021
    Assignee: Seattle Children's Hospital
    Inventor: Michael C. Jensen
  • Patent number: 11111283
    Abstract: The present invention provides new protease resistant polypeptides, as well as compositions and methods for treating, ameliorating or preventing conditions related to joint damage, including acute joint injury and arthritis.
    Type: Grant
    Filed: February 7, 2019
    Date of Patent: September 7, 2021
    Assignee: NOVARTIS AG
    Inventors: Kristen Johnson, Jian Shi
  • Patent number: 11110176
    Abstract: Embodiments of the disclosure pertain to compositions containing (i) one or more non-antifreeze proteins or cell components or cells and (ii) one or more antifreeze proteins (AFPs), mimetics thereof, and/or analogs thereof, and a method of stabilizing a biologic (e.g., a protein, microbe, cell component or cell) against temperature stress and aggregation. The AFP may be selected from known antifreeze polypeptides and antifreeze peptides, analogs and mimetics of antifreeze proteins, active fragments of such antifreeze proteins, polypeptide and peptide mimetics, antifreeze peptoids and polymers, and combinations thereof. The non-antifreeze protein, cell component or cell comprises a known protein, cell component or cell used in the pharmaceutical, medical, agricultural, veterinary and/or food industry(ies). The AFP protects the function of the non-antifreeze protein, microbe(s), cell component(s) or cell(s) under temperature stress (e.g., a temperature of ?20-60° C.).
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: September 7, 2021
    Assignee: The Board of Trustees of the California State University
    Inventor: Xin Wen
  • Patent number: 11104711
    Abstract: Compounds are provided herein for inducing weight loss and for treating diabetes, dyslipidemia, NASH and/or obesity. Also provided are pharmaceutical compositions containing such compounds and therapeutic uses of such compounds and compositions, where such compounds act as GDF15 agonists with extended time of action and other advantageous properties.
    Type: Grant
    Filed: March 29, 2019
    Date of Patent: August 31, 2021
    Assignee: Eli Lilly and Company
    Inventors: Malgorzata Donata Gonciarz, Victor H. Obungu, Richard Todd Pickard
  • Patent number: 11098091
    Abstract: Mutant M-CSF protein, comprising ?v?3 integrin binding motif and pharmaceutical compositions comprising same, are provided. Further, use of the composition for the treatment and or prevention of diseases associated with increased bone resorption are provided.
    Type: Grant
    Filed: August 17, 2017
    Date of Patent: August 24, 2021
    Assignees: THE NATIONAL INSTITUTE FOR BIOTECHNOLOGY IN THE NEGEV LTD., B. G. NEGEV TECHNOLOGIES AND APPLICATIONS LTD., AT BEN-GURION UNIVERSITY
    Inventors: Niv Papo, Noam Levaot, Yuval Zur, Lior Rosenfeld
  • Patent number: 11098363
    Abstract: The disclosure provides nucleic acid molecules, including cDNA, comprising an alteration that encodes a loss-of-function cornulin (CRNN) protein. The disclosure also provides isolated and recombinant human loss-of-function cornulin protein variants that comprise a truncation at a position corresponding to position 79. The truncation, and the nucleic acid molecules encoding this change, associate with skin disorders such as, for example, psoriasis, eczema, or atopic dermatitis. The disclosure also provides methods for determining whether a subject has or has a risk of developing a skin disorder, based on the identification of such alterations in the nucleic acid molecules encoding CRNN. Subjects at risk for or who have a skin disorder may be treated with an agent effective to treat the skin disorder.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: August 24, 2021
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Claudia Gonzaga-Jauregui, Kavita Praveen
  • Patent number: 11098329
    Abstract: One aspect of the invention relates to a mutant polypeptide comprising the amino acid sequence of Escherichia coli tetracycline efflux pump A (TetA). Another aspect of the invention relates to a polynucleotide encoding a polypeptide of TetA, a fragment thereof, or a mutant thereof. Another aspect of the invention relates to a first expression plasmid vector comprising one or more first polynucleotides encoding a first polypeptide comprising a tetracycline efflux pump polypeptide, a fragment thereof or a mutant thereof, one or more second polynucleotides independently selected from the group consisting of a third polynucleotide encoding a third polypeptide comprising a lysine decarboxylase polypeptide, a fragment thereof or a mutant thereof, and a fourth polynucleotide encoding a fourth polypeptide comprising a lysine biosynthesis polypeptide, a fragment thereof or a mutant thereof.
    Type: Grant
    Filed: July 17, 2019
    Date of Patent: August 24, 2021
    Assignees: CATHAY BIOTECH INC., CIBT AMERICA INC.
    Inventors: Howard Chou, Xiucai Liu
  • Patent number: 11098107
    Abstract: The present disclosure relates to antibodies and antibody conjugates having one or more site-specific mutations in the CH2 domain of the heavy chain. The antibody variants disclosed herein can have improved characteristics (e.g., thermal stability, antibody yields, antibody titers, cell-killing) relative to a parent or wild type antibody, including aglycosylated parent or wild type antibodies. Pharmaceutical compositions, diagnostic compositions and kits comprising the same, as well as methods of using these compositions and kits for therapeutic and diagnostic purposes, are also described.
    Type: Grant
    Filed: June 14, 2017
    Date of Patent: August 24, 2021
    Assignee: SUTRO BIOPHARMA, INC.
    Inventors: Daniel Calarese, Gang Yin